Company Overview
Precipio, Inc. operates within the healthcare sector, specifically focusing on the diagnostics and research industry, where it provides essential cancer diagnostic products, reagents, and services across the United States market. The company's core business involves delivering diagnostic blood cancer testing services and utilizing its proprietary cell culture media known as IV-Cell to facilitate the simultaneous culturing of four hematopoietic cell lines, thereby supporting advanced research and clinical applications. This specialized biotechnology entity employs a workforce of 54 individuals, reflecting a mid-sized operational scale typical for niche research-focused firms. With a current market capitalization of $45.50M and annual revenue reaching $22.80M, the company's valuation suggests it is a smaller-cap asset with significant potential for expansion, yet the limited revenue base indicates it remains in a growth phase rather than a mature market dominance position.
Financial Health
The company reported revenue of $22.80M over the trailing twelve months, yet recorded a net income loss of $-1,254,000 and an EBITDA of $-685,000, a divergence that reveals a substantial cost structure burdened by high operating expenses relative to top-line generation. Despite the net loss, the company generated positive free cash flow of $765,250, which provides critical financial flexibility to fund ongoing research and development without immediate reliance on external equity financing. The gross margin stands at 44.8%, indicating healthy pricing power and cost control in production, whereas the operating margin of -0.9% and profit margin of -5.5% highlight significant overhead costs that suppress overall profitability before accounting for tax and interest factors. On the balance sheet, Precipio, Inc. holds $2.31M in cash against $3.56M in debt, resulting in a high debt-to-equity ratio of 25.91, which characterizes a leveraged balance sheet rather than a conservative one. Liquidity is supported by a current ratio of 1.27, suggesting the firm possesses sufficient current assets to cover its short-term liabilities, though the margin is not excessively high. Return on equity is recorded at -9.8% and return on assets at -6.8%, metrics that indicate management is currently generating negative returns on shareholder capital and total assets, reflecting the investment-heavy nature of the biotechnology sector.
Valuation Assessment
Valuation metrics for Precipio, Inc. show a trailing P/E ratio of N/A due to the lack of recent earnings, while the forward P/E is calculated at 66.59, implying that the market prices in significant future earnings growth to justify the current share price. The price-to-book ratio is 3.30, indicating that the stock trades at a substantial premium over its book value, which is common for biotechnology firms with intangible assets and intellectual property that are not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 2.00 and the EV/EBITDA of -68.26 provide context, suggesting the company is valued based on revenue multiples due to its negative earnings, while the negative EV/EBITDA reflects its current inability to generate positive enterprise earnings. The stock has demonstrated significant volatility within the past year, trading between a 52-week low of $3.90 and a 52-week high of $29.53. At the time of the latest data point, the stock price sits significantly below the 52-week high, representing a trading position that is approximately 86.7% below the recent peak, highlighting the disparity between market sentiment and recent performance highs. The beta of 1.25 indicates that the stock's price volatility is 25% higher than the broader market, exposing investors to greater systemic risk during market downturns.
Growth & Income
Precipio, Inc. demonstrated robust revenue growth of 29.9% year over year, while earnings growth is listed as N/A due to the company's continued losses, indicating that top-line expansion is outpacing profitability in the current fiscal period. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are reinvested back into the business rather than distributed to shareholders. Since the company is not a dividend payer, the capital generated from operations and potential future profits will be directed toward research initiatives, product development, and operational scaling to drive future valuation growth. The overall growth and income profile presents a classic early-stage biotechnology narrative characterized by high revenue expansion and zero income distribution, relying entirely on future operational success to convert current losses into sustainable profits.